SUSAN G KOMEN BREAST CANCER FOUNDATION: Form 990, tax year 2023

View the entire original 990 at ProPublica ↗

Organization: SUSAN G KOMEN BREAST CANCER FOUNDATION (EIN 75-1835298)
Tax period: 2023-04-01 to 2024-03-31
Filed: 2024-12-23
IRS object ID: 202443589349301124
Schema version: 2023v5.1
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2024-12-23T19:10:22+00:00	ReturnTs
Tax Period End	2024-03-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	346565596	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	ERNST & YOUNG US LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	560 MISSION STREET	AddressLine1Txt
City	SAN FRANCISCO	CityNm
State Abbreviation	CA	StateAbbreviationCd
ZIP	941052907	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2023-04-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	751835298	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	The Susan G Komen Breast Cancer Foundation Inc	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	SUSA	BusinessNameControlTxt
Phone	9728551600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 NOEL ROAD SUITE 801889	AddressLine1Txt
City	DALLAS	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	PAULA SUE SCHNEIDER	PersonNm
Person Title	PRESIDENT AND CEO	PersonTitleTxt
Phone	9728551600	PhoneNum
Signature	2024-12-24	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	Eva Nitta	PreparerPersonNm
PTIN	P01286320	PTIN
Phone	4158948000	PhoneNum
Preparation	2024-12-24	PreparationDt

Field	Value	IRS element (for citing)
Tax	2023	TaxYr
Build TS	2024-10-15 13:58:12Z	BuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

Field	Value	IRS element (for citing)
Business Name Line1	SUSAN G KOMEN	BusinessNameLine1Txt

Principal Ofcr Business Name PrincipalOfcrBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	PAULA SUE SCHNEIDER	BusinessNameLine1Txt

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 NOEL ROAD SUITE 801889	AddressLine1Txt
City	DALLAS	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$141,860,986	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.KOMEN.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1982	FormationYr
Legal Domicile State	TX	LegalDomicileStateCd
Activity Or Mission	OUR MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER.	ActivityOrMissionDesc
Voting Members Governing Body	18	VotingMembersGoverningBodyCnt
Voting Members Independent	18	VotingMembersIndependentCnt
Total Employee	492	TotalEmployeeCnt
Total Volunteers	7928	TotalVolunteersCnt
Total Gross UBI	$16,441	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$111,805,407	PYContributionsGrantsAmt
CY Contributions Grants	$98,107,413	CYContributionsGrantsAmt
CY Program Service Revenue	$0	CYProgramServiceRevenueAmt
PY Investment Income	$2,453,577	PYInvestmentIncomeAmt
CY Investment Income	$11,825,383	CYInvestmentIncomeAmt
PY Other Revenue	-$6,661,279	PYOtherRevenueAmt
CY Other Revenue	-$6,998,610	CYOtherRevenueAmt
PY Total Revenue	$107,597,705	PYTotalRevenueAmt
CY Total Revenue	$102,934,186	CYTotalRevenueAmt
PY Grants And Similar Paid	$29,280,228	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$22,270,944	CYGrantsAndSimilarPaidAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$45,865,289	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$47,674,560	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$1,363,728	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$1,364,005	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$26,299,631	CYTotalFundraisingExpenseAmt
PY Other Expenses	$40,554,624	PYOtherExpensesAmt
CY Other Expenses	$40,180,095	CYOtherExpensesAmt
PY Total Expenses	$117,063,869	PYTotalExpensesAmt
CY Total Expenses	$111,489,604	CYTotalExpensesAmt
PY Revenues Less Expenses	-$9,466,164	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$8,555,418	CYRevenuesLessExpensesAmt
Total Assets BOY	$192,631,082	TotalAssetsBOYAmt
Total Assets EOY	$188,139,545	TotalAssetsEOYAmt
Total Liabilities BOY	$62,957,218	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$58,636,745	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$129,673,864	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$129,502,800	NetAssetsOrFundBalancesEOYAmt
Mission	SUSAN G. KOMEN HAS AN UNMATCHED, COMPREHENSIVE 360-DEGREE APPROACH TO FIGHTING BREAST CANCER ACROSS ALL FRONTS AND SUPPORTING MILLIONS OF PEOPLE IN THE U.S. AND IN COUNTRIES WORLDWIDE. WE ADVOCATE FOR PATIENTS, DRIVE RESEARCH BREAKTHROUGHS, IMPROVE ACCESS TO HIGH-QUALITY CARE, OFFER DIRECT PATIENT SUPPORT AND EMPOWER PEOPLE WITH TRUSTWORTHY INFORMATION. KOMEN REMAINS COMMITTED TO SUPPORTING THOSE AFFECTED BY BREAST CANCER TODAY, WHILE TIRELESSLY SEARCHING FOR TOMORROW'S CURES.	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$50,763,523	ExpenseAmt
Grant	$12,401,652	GrantAmt
Revenue	$0	RevenueAmt
Desc	PATIENT CARE: PROVISION OF BREAST CANCER PATIENT NAVIGATION, SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS DIRECTLY BY KOMEN AND THROUGH GRANTS TO OTHER NON-PROFIT ORGANIZATIONS AND THIRD-PARTY CONTRACTS, WITH A FOCUS ON SERVING COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$17,715,813	ExpenseAmt
Grant	$9,869,292	GrantAmt
Revenue	$0	RevenueAmt
Desc	RESEARCH: KOMEN-LED RESEARCH & SCIENTIFIC PROGRAMS AND GRANTS TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED ON RESEARCH PRIORITIES THAT SERVE TO MAKE THE BIGGEST DIFFERENCE FOR PATIENTS: CONQUERING METASTATIC AND AGGRESSIVE BREAST CANCERS, ADVANCING PERSONALIZED BREAST CARE AND ELIMINATING BREAST CANCER DISPARITIES AND INEQUITIES. SEE SCHEDULE O FOR ADDITIONAL DETAILS.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$4,654,734	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$0	RevenueAmt
Desc	PUBLIC POLICY AND ADVOCACY: INITIATIVES THAT HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER, INCLUDING ACTIVITIES ADVOCATING FOR LEGISLATIVE, REGULATORY AND OTHER POLICY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE, AND FUND CRITICAL BREAST CANCER RESEARCH. SEE SCHEDULE O FOR DETAILS.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$73,134,070	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	false	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (true)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	Yes (true)	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	false	ReportOtherAssetsInd
Report Other Liabilities	false	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	false	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (true)	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	false	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (true)	ProfessionalFundraisingInd
Fundraising Activities	Yes (true)	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	Yes (true)	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	false	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (true)	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	false	DisregardedEntityInd
Related Entity	false	RelatedEntityInd
Related Organization Ctrl Ent	false	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	233	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	492	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (true)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (true)	Form990TFiledInd
Foreign Financial Account	false	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (true)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (true)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	Yes (true)	Form8282PropertyDisposedOfInd
Form8282 Filed	1	Form8282FiledCnt
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	false	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	false	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	18	GoverningBodyVotingMembersCnt
Independent Voting Member	18	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	false	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	Yes (true)	LocalChaptersInd
Policies Reference Chapters	Yes (true)	PoliciesReferenceChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DE	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	LA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RIA WILLIAMS	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	9728551600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 NOEL ROAD SUITE 801889	AddressLine1Txt
City	DALLAS	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (30 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
Ed Dandridge
Chair of the Board	1.0	0	Yes (X)	Yes (X)	$0	$0	$0
Jerri Johnson
BOD MEMBER (VICE CHAIR)	1.0	0	Yes (X)	Yes (X)	$0	$0	$0
BJ Schaknowski
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Boris Dolgonos
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Charles Rockefeller
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Christina Minnis
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Elizabeth Saint-Aignan
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Gail Heimann
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Julie Gruber
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Kathy Sutherland
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Kim Blackwell
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Kristen Maple
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Luke Sauter
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Lydia The
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Michelle Bottomley
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Peter Brundage
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Robyn Shepherd
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Valerie Rainey
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Eunice Nakamura
General Counsel and Corporate Secretary	55.0	0		Yes (X)	$288,277	$0	$24,192
Paula Schneider
President and CEO	55.0	0		Yes (X)	$936,700	$0	$40,568
Ria Williams
Chief Fin & Ops Officer	55.0	0		Yes (X)	$339,735	$0	$48,233
Catherine Olivieri
SVP, Human Resources	55.0	0			$284,819	$0	$31,221	Yes (X)
Kathryn Watt
VP, Marketing Strategy	55.0	0			$234,686	$0	$8,628	Yes (X)
Sarah Rosales
VP, Corporate Partnerships	55.0	0			$265,317	$0	$32,342	Yes (X)
Victoria Smart
SVP, Mission	55.0	0			$336,530	$0	$21,751	Yes (X)
Catherine Stone
VP, Community Health	55.0	0			$217,001	$0	$14,809		Yes (X)
Kari Bodell
VP, Development Programs Strategy	55.0	0			$241,745	$0	$15,926		Yes (X)
Kim Sabelko
VP, Scientific Strategy & Programs	55.0	0			$213,062	$0	$23,943		Yes (X)
Lori Maris
SVP, OPS SERVICES & SUPPORT	55.0	0			$205,316	$0	$15,867		Yes (X)
Rachel Davies
VP, Marketing & Communications	55.0	0			$193,992	$0	$15,483		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$3,757,180	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$292,963	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	134	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	false	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt	Address Line2ContractorAddress/USAddress/AddressLine2Txt
Event 360
205 N Michigan Ave	Chicago	IL	60601	Event Management	$3,542,412
RKD Group LLC
3400 Waterview Parkway	Richardson	TX	75080	Consulting	$807,901
Splick 13 Assoc DBA Reinvent the World
33 Aldridge Rd	Chappaque	NY	10514	Fundraising consulting	$383,739
Ernst & Young
2323 Victory Avenue	Dallas	TX	75219	Acctg & Tax Services	$346,207	Suite 2000
Dana-Farber Cancer Institute Inc
450 Brookline Avenue	Boston	MA	022155450	PROGRAM SERVICES	$309,665	Mailstop BP437

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	14	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$316,005	FederatedCampaignsAmt
Membership Dues	$0	MembershipDuesAmt
Fundraising	$33,702,650	FundraisingAmt
Related Organizations	$0	RelatedOrganizationsAmt
Government Grants	$0	GovernmentGrantsAmt
All Other Contributions	$64,088,758	AllOtherContributionsAmt
Noncash Contributions	$411,191	NoncashContributionsAmt
Total Contributions	$98,107,413	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp (5 entries)

Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt	ExclusionExclusionAmt
$0	$0	$0	$0
$0	$0	$0	$0
$0	$0	$0	$0
$0	$0	$0	$0
$0	$0	$0	$0

Total Oth Program Service Rev TotalOthProgramServiceRevGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$0	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$12,825,488	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$12,825,488	ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Gross Rents GrossRentsGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Less Rental Expenses LessRentalExpensesGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$29,058,227	SecuritiesAmt
Other	$0	OtherAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$30,058,332	SecuritiesAmt
Other	$0	OtherAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	-$1,000,105	SecuritiesAmt
Other	$0	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$1,000,105	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	-$1,000,105	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$1,643,905	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$33,702,650	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$8,811,724	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$7,167,819	TotalRevenueColumnAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	-$7,167,819	ExclusionAmt

Field	Value	IRS element (for citing)
Gaming Gross Income	$3,900	GamingGrossIncomeAmt
Gaming Direct Expenses	$0	GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$3,900	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$3,900	ExclusionAmt

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	$154,891	GrossSalesOfInventoryAmt
Cost Of Goods Sold	$56,744	CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$98,147	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$98,147	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt	ExclusionExclusionAmt
OTHER INCOME	900099	$67,162	$0	$16,441	$50,721
		$0	$0	$0	$0
		$0	$0	$0	$0

Miscellaneous Revenue MiscellaneousRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$67,162	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$102,934,186	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$16,441	UnrelatedBusinessRevenueAmt
Exclusion	$4,810,332	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$11,332,694	TotalAmt
Program Services	$11,332,694	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$10,904,250	TotalAmt
Program Services	$10,904,250	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$34,000	TotalAmt
Program Services	$34,000	ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,893,000	TotalAmt
Program Services	$1,562,220	ProgramServicesAmt
Management And General	$578,600	ManagementAndGeneralAmt
Fundraising	$752,180	FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$37,092,121	TotalAmt
Program Services	$20,068,753	ProgramServicesAmt
Management And General	$7,318,669	ManagementAndGeneralAmt
Fundraising	$9,704,699	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$1,535,444	TotalAmt
Program Services	$852,374	ProgramServicesAmt
Management And General	$281,808	ManagementAndGeneralAmt
Fundraising	$401,262	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$3,491,842	TotalAmt
Program Services	$1,909,240	ProgramServicesAmt
Management And General	$745,398	ManagementAndGeneralAmt
Fundraising	$837,204	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$2,662,153	TotalAmt
Program Services	$1,451,743	ProgramServicesAmt
Management And General	$489,604	ManagementAndGeneralAmt
Fundraising	$720,806	FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$220,906	TotalAmt
Program Services	$89,026	ProgramServicesAmt
Management And General	$65,326	ManagementAndGeneralAmt
Fundraising	$66,554	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$365,958	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$365,958	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$320,990	TotalAmt
Program Services	$320,990	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$1,364,005	TotalAmt
Fundraising	$1,364,005	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$6,662,513	TotalAmt
Program Services	$4,023,378	ProgramServicesAmt
Management And General	$208,904	ManagementAndGeneralAmt
Fundraising	$2,430,231	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$13,567,602	TotalAmt
Program Services	$6,901,812	ProgramServicesAmt
Management And General	$83,882	ManagementAndGeneralAmt
Fundraising	$6,581,908	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$2,045,064	TotalAmt
Program Services	$838,475	ProgramServicesAmt
Management And General	$633,971	ManagementAndGeneralAmt
Fundraising	$572,618	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$173,106	TotalAmt
Program Services	$127,172	ProgramServicesAmt
Management And General	$1,363	ManagementAndGeneralAmt
Fundraising	$44,571	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$1,182,529	TotalAmt
Program Services	$795,801	ProgramServicesAmt
Management And General	$112,869	ManagementAndGeneralAmt
Fundraising	$273,859	FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$205,887	TotalAmt
Program Services	$142,991	ProgramServicesAmt
Management And General	$18,048	ManagementAndGeneralAmt
Fundraising	$44,848	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Payments To Affiliates PaymentsToAffiliatesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$1,516,039	TotalAmt
Program Services	$1,332,138	ProgramServicesAmt
Management And General	$96,626	ManagementAndGeneralAmt
Fundraising	$87,275	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$521,874	TotalAmt
Program Services	$521,874	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
CONSULT & PROF. FEES	$6,531,076	$5,680,362	$385,934	$464,780
EQUIP RENTAL & MAINT	$3,626,315	$2,443,185	$315,841	$867,289
MERCHANT SERVICES & BANK FEES	$1,785,321	$971,641	$83,610	$730,070
EVENT PRODUCTION	$439,688	$324,270	$32,393	$83,025

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$1,015,227	TotalAmt
Program Services	$505,681	ProgramServicesAmt
Management And General	$237,099	ManagementAndGeneralAmt
Fundraising	$272,447	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$111,489,604	TotalAmt
Program Services	$73,134,070	ProgramServicesAmt
Management And General	$12,055,903	ManagementAndGeneralAmt
Fundraising	$26,299,631	FundraisingAmt

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$48,354,604	TotalAmt
Program Services	$24,397,947	ProgramServicesAmt
Management And General	$1,947,866	ManagementAndGeneralAmt
Fundraising	$22,008,791	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$11,205,049	BOYAmt
EOY	$16,541,435	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$15,405,966	BOYAmt
EOY	$15,796,832	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$47,380	BOYAmt
EOY	$15,990	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$1,613,365	BOYAmt
EOY	$2,007,298	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$14,740,860	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$11,095,444	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$4,353,535	BOYAmt
EOY	$3,645,416	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$114,281,787	BOYAmt
EOY	$114,278,903	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$43,470,000	BOYAmt
EOY	$33,480,000	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$2,254,000	BOYAmt
EOY	$2,373,671	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$192,631,082	BOYAmt
EOY	$188,139,545	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$9,306,708	BOYAmt
EOY	$6,826,023	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$53,366,811	BOYAmt
EOY	$51,574,727	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$283,699	BOYAmt
EOY	$235,995	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$62,957,218	BOYAmt
EOY	$58,636,745	EOYAmt

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$84,243,927	BOYAmt
EOY	$88,459,438	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$45,429,937	BOYAmt
EOY	$41,043,362	EOYAmt

Cap Stk Tr Prin Current Funds CapStkTrPrinCurrentFundsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Pd In Cap Srpls Land Bldg Eqp Fund PdInCapSrplsLandBldgEqpFundGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rtn Earn Endowment Incm Oth Fnds RtnEarnEndowmentIncmOthFndsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$129,673,864	BOYAmt
EOY	$129,502,800	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$192,631,082	BOYAmt
EOY	$188,139,545	EOYAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	Yes (X)	InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss	-$8,555,418	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$7,977,937	NetUnrlzdGainsLossesInvstAmt
Donated Services And Use Fclts	$145,786	DonatedServicesAndUseFcltsAmt
Investment Expense	-$375,019	InvestmentExpenseAmt
Prior Period Adjustments	$0	PriorPeriodAdjustmentsAmt
Other Changes In Net Assets	$635,650	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	false	FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$59,972,314	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$50,983,746	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$99,456,148	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$111,805,407	CurrentTaxYearMinus1YearAmt
Current Tax Year	$98,107,413	CurrentTaxYearAmt
Total	$420,325,028	TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$59,972,314	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$50,983,746	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$99,456,148	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$111,805,407	CurrentTaxYearMinus1YearAmt
Current Tax Year	$98,107,413	CurrentTaxYearAmt
Total	$420,325,028	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$12,442,764	SubstantialContributorsTotAmt
Public Support Total170	$407,882,264	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$4,928,838	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$1,217,543	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,156,360	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$1,438,781	CurrentTaxYearMinus1YearAmt
Current Tax Year	$12,830,552	CurrentTaxYearAmt
Total	$21,572,074	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Current Tax Year	$16,441	CurrentTaxYearAmt
Total	$16,441	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$86,442	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$15,070	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$3,574	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$26,758	CurrentTaxYearMinus1YearAmt
Current Tax Year	$50,721	CurrentTaxYearAmt
Total	$182,565	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$442,096,108	TotalSupportAmt
Gross Receipts Rltd Activities	$66,875,475	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.9226	PublicSupportCY170Pct
Public Support PY170	0.9170	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule A, Part II, Line 10 Other Income	FormAndLineReferenceDesc
Explanation	DESCRIPTION - OTHER INCOME, COLUMN A - 86442.0, COLUMN B - 15070.0, COLUMN C - 3574.0, COLUMN D - 26758.0, COLUMN E - 50721.0, COLUMN F - 182565.0;	ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Total Grassroots Lobbying TotalGrassrootsLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$20,317	FilingOrganizationsTotalAmt
Affiliated Group Total	$20,317	AffiliatedGroupTotalAmt

Total Direct Lobbying TotalDirectLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$300,673	FilingOrganizationsTotalAmt
Affiliated Group Total	$300,673	AffiliatedGroupTotalAmt

Total Lobbying Expend TotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$320,990	FilingOrganizationsTotalAmt
Affiliated Group Total	$320,990	AffiliatedGroupTotalAmt

Other Exempt Purpose Expend OtherExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$99,112,711	FilingOrganizationsTotalAmt
Affiliated Group Total	$99,112,711	AffiliatedGroupTotalAmt

Total Exempt Purpose Expend TotalExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$99,433,701	FilingOrganizationsTotalAmt
Affiliated Group Total	$99,433,701	AffiliatedGroupTotalAmt

Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$1,000,000	FilingOrganizationsTotalAmt
Affiliated Group Total	$1,000,000	AffiliatedGroupTotalAmt

Grassroots Nontaxable GrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$250,000	FilingOrganizationsTotalAmt
Affiliated Group Total	$250,000	AffiliatedGroupTotalAmt

Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt
Affiliated Group Total	$0	AffiliatedGroupTotalAmt

Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt
Affiliated Group Total	$0	AffiliatedGroupTotalAmt

Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$1,000,000	CurrentYearMinus3Amt
Current Year Minus2	$1,000,000	CurrentYearMinus2Amt
Current Year Minus1	$1,000,000	CurrentYearMinus1Amt
Current Year	$1,000,000	CurrentYearAmt
Total	$4,000,000	TotalAmt

Field	Value	IRS element (for citing)
Lobbying Ceiling	$6,000,000	LobbyingCeilingAmt

Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$172,474	CurrentYearMinus3Amt
Current Year Minus2	$204,997	CurrentYearMinus2Amt
Current Year Minus1	$293,520	CurrentYearMinus1Amt
Current Year	$320,990	CurrentYearAmt
Total	$991,981	TotalAmt

Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$250,000	CurrentYearMinus3Amt
Current Year Minus2	$250,000	CurrentYearMinus2Amt
Current Year Minus1	$250,000	CurrentYearMinus1Amt
Current Year	$250,000	CurrentYearAmt
Total	$1,000,000	TotalAmt

Field	Value	IRS element (for citing)
Grassroots Ceiling	$1,500,000	GrassrootsCeilingAmt

Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$386,160	CurrentYearMinus3Amt
Current Year Minus2	$26,906	CurrentYearMinus2Amt
Current Year Minus1	$15,803	CurrentYearMinus1Amt
Current Year	$20,317	CurrentYearAmt
Total	$449,186	TotalAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule C, Part II-A Lobbying Expenses	FormAndLineReferenceDesc
Explanation	PUBLIC POLICY AND ADVOCACY INITIATIVES HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER. RECOGNIZING THE IMPORTANCE OF THIS WORK TO ACCOMPLISH ITS MISSION, KOMEN SUPPORTS LIMITED LOBBYING ACTIVITIES TO ACHIEVE LEGISLATIVE AND REGULATORY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE AND FUND CRITICAL BREAST CANCER RESEARCH.	ExplanationTxt

Schedule D IRS990ScheduleD

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$3,612,548	BeginningYearBalanceAmt
Contributions	$133,367	ContributionsAmt
Investment Earnings Or Losses	$26,029	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$145,372	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$3,626,572	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,346,868	BeginningYearBalanceAmt
Contributions	$2,279,000	ContributionsAmt
Investment Earnings Or Losses	-$7,607	InvestmentEarningsOrLossesAmt
Other Expenditures	$5,713	OtherExpendituresAmt
End Year Balance	$3,612,548	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,342,173	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	$10,613	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$5,918	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,346,868	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,337,562	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	$10,279	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$5,668	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,342,173	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,333,603	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	$9,803	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$5,844	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,337,562	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.276	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.718	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.006	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd

Land LandGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$0	OtherCostOrOtherBasisAmt
Book Value	$0	BookValueAmt

Buildings BuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$0	OtherCostOrOtherBasisAmt
Depreciation	$0	DepreciationAmt
Book Value	$0	BookValueAmt

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$83,890	OtherCostOrOtherBasisAmt
Depreciation	$83,890	DepreciationAmt
Book Value	$0	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$2,461,620	OtherCostOrOtherBasisAmt
Depreciation	$2,204,979	DepreciationAmt
Book Value	$256,641	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$12,195,350	OtherCostOrOtherBasisAmt
Depreciation	$8,806,575	DepreciationAmt
Book Value	$3,388,775	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$3,645,416	TotalBookValueLandBuildingsAmt

Other Securities OtherSecuritiesGrp

Field	Value	IRS element (for citing)
Desc	PRIVATE EQUITY FUND	Desc
Book Value	$33,480,000	BookValueAmt
Method Valuation	F	MethodValuationCd

Field	Value	IRS element (for citing)
Total Book Value Securities	$33,480,000	TotalBookValueSecuritiesAmt
Total Liability	$0	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$144,909,786	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$7,977,937	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$34,337,005	DonatedServicesAndUseFcltsAmt
Recoveries Prior Year Grants	$0	RecoveriesPriorYearGrantsAmt
Other Revenue	$35,677	OtherRevenueAmt
Revenue Not Reported	$42,350,619	RevenueNotReportedAmt
Revenue Subtotal	$102,559,167	RevenueSubtotalAmt
Investment Expenses Not Incld	$375,019	InvestmentExpensesNotIncldAmt
Other Revenues Not Included	$0	OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt	$375,019	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$102,934,186	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$145,080,850	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$34,191,217	DonatedServicesUseFcltsAmt
Prior Year Adjustments	$0	PriorYearAdjustmentsAmt
Losses Reported	$0	LossesReportedAmt
Other Expenses Included	$35,679	OtherExpensesIncludedAmt
Expenses Not Reported	$34,226,896	ExpensesNotReportedAmt
Expenses Subtotal	$110,853,954	ExpensesSubtotalAmt
Other Expenses Not Included	$635,650	OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt	$635,650	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$111,489,604	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (5 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Schedule D, Part V, Line 4 Intended uses of endowment funds	KOMEN HAS FIVE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, TWO GENERAL ENDOWMENTS, AND A PERPETUAL TRUST. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, THE GENERAL ENDOWMENT AND PERPETUAL TRUST'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES. ADDITIONALLY, THERE IS ONE GENERAL ENDOWMENT FUND ESTABLISHED BY THE BOARD OF DIRECTORS.
Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote	THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2024
Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990	PROGRAM COGS - 35677
Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990	PROGRAM COGS - 35677 ROUNDING - 2
Schedule D, Part XII, Line 4(b) Other expenses in form 990 not in audited financial statements	RESCINDED GRANTS - 635650

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (9 entries)

RegionRegionTxt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
Europe (Including Iceland and Greenland)	1	Fundraising	Fundraising Support	$12,806
Europe (Including Iceland and Greenland)	2	Grantmaking	Research	$34,000
Europe (Including Iceland and Greenland)	1	Program Services	Learning Mgmt System	$17,175
Europe (Including Iceland and Greenland)	1	Program Services	Mission Tool Development	$30,375
Europe (Including Iceland and Greenland)	1	Program Services	Legal Services	$21,897
North America (Canada & Mexico only)	2	Program Services	Mission Support	$70,562
North America (Canada & Mexico only)	1	Program Services	Professional Membership	$2,000
North America (Canada & Mexico only)	1	Program Services	Research	$1,276
North America (Canada & Mexico only)	1	Program Services	Software Licenses	$17,270

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	11	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	11	TotalEmployeeCnt
Subtotal Spent	$207,361	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$207,361	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (3 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt
Europe (Including Iceland and Greenland)	Research	$9,000	Electronic Fund Transfer
Europe (Including Iceland and Greenland)	Research	$6,000	Electronic Fund Transfer
Europe (Including Iceland and Greenland)	Research	$19,000	Electronic Fund Transfer

Field	Value	IRS element (for citing)
Total501c3 Org	3	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt
Transfer To Foreign Corp	Yes (true)	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	Yes (true)	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	false	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds	AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR GRANTS, ALL GRANTEES ARE REQUIRED TO SUBMIT PROGRESS REPORTS AND FINANCIAL REPORTS IN THE FORMAT REQUIRED BY KOMEN AND IN ACCORDANCE WITH THE SCHEDULE SET FORTH IN THE POLICIES AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV AND SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.
Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements	EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual
Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements	EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Phone Solicitations	Yes (X)	PhoneSolicitationsInd
In Person Solicitations	Yes (X)	InPersonSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (true)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (3 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd	Gross ReceiptsGrossReceiptsAmt	Retained By ContractorRetainedByContractorAmt	Net To OrganizationNetToOrganizationAmt
Event 360
55 E Jackson Blvd Suite 1010	Chicago	IL	60604	Fundraising Consultant	false	$13,596,382	$913,565	$12,682,817
Revunami Inc
228 E 85th St Suite 9C	New York	NY	10028	Marketing Consultant	false		$2,750	-$2,750
RKD Group LLC
3400 Waterview Parkway Suite 250	Richardson	TX	75080	Fundraising Consultant	false	$22,789,288	$447,690	$22,341,598

Field	Value	IRS element (for citing)
Total Gross Receipts	$36,385,670	TotalGrossReceiptsAmt
Total Retained By Contractors	$1,364,005	TotalRetainedByContractorsAmt
Total Net To Organization	$35,021,665	TotalNetToOrganizationAmt
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	DC	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	AL	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	ID	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	IN	LicensedStatesCd
Licensed States	IA	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	LA	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	AK	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MN	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	MT	LicensedStatesCd
Licensed States	NE	LicensedStatesCd
Licensed States	NV	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NY	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	AZ	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	SD	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	TX	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WV	LicensedStatesCd
Licensed States	WI	LicensedStatesCd
Licensed States	WY	LicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	3 Day Series	Event1Nm
Gross Receipts Event1	$13,596,382	GrossReceiptsEvent1Amt
Charitable Contri Event1	$13,356,356	CharitableContriEvent1Amt
Gross Revenue Event1	$240,026	GrossRevenueEvent1Amt
Cash Prizes Event1	$0	CashPrizesEvent1Amt
Non Cash Prizes Event1	$12,326	NonCashPrizesEvent1Amt
Rent Facility Costs Event1	$2,507,548	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$498,621	FoodAndBeverageEvent1Amt
Entertainment Event1	$0	EntertainmentEvent1Amt
Other Direct Expenses Event1	$1,473,590	OtherDirectExpensesEvent1Amt
Event2	Race-Walk Events	Event2Nm
Gross Receipts Event2	$19,656,596	GrossReceiptsEvent2Amt
Charitable Contri Event2	$18,623,129	CharitableContriEvent2Amt
Gross Revenue Event2	$1,033,467	GrossRevenueEvent2Amt
Cash Prizes Event2	$0	CashPrizesEvent2Amt
Non Cash Prizes Event2	$417,598	NonCashPrizesEvent2Amt
Rent Facility Costs Event2	$299,252	RentFacilityCostsEvent2Amt
Food And Beverage Event2	$330,283	FoodAndBeverageEvent2Amt
Entertainment Event2	$16,767	EntertainmentEvent2Amt
Other Direct Expenses Event2	$2,367,772	OtherDirectExpensesEvent2Amt
Gross Receipts Other Events	$2,093,577	GrossReceiptsOtherEventsAmt
Charitable Contri Other Events	$1,723,165	CharitableContriOtherEventsAmt
Gross Revenue Other Events	$370,412	GrossRevenueOtherEventsAmt
Cash Prizes Other Events	$0	CashPrizesOtherEventsAmt
Non Cash Prizes Other Events	$47,857	NonCashPrizesOtherEventsAmt
Rent Fclty Costs Other Events	$143,907	RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events	$2,992	FoodAndBeverageOtherEventsAmt
Entertainment Other Events	$25,104	EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events	$668,107	OthDirectExpnssOtherEventsAmt
Gross Receipts Total	$35,346,555	GrossReceiptsTotalAmt
Charitable Contributions Tot	$33,702,650	CharitableContributionsTotAmt
Gross Revenue Total Events	$1,643,905	GrossRevenueTotalEventsAmt
Cash Prizes Total Events	$0	CashPrizesTotalEventsAmt
Non Cash Prizes Total Events	$477,781	NonCashPrizesTotalEventsAmt
Rent Fclty Costs Total Events	$2,950,707	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$831,896	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$41,871	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$4,509,469	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$8,811,724	DirectExpenseSummaryEventsAmt
Net Income Summary	-$7,167,819	NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule G, Part II Net Income Summary	FormAndLineReferenceDesc
Explanation	Gross receipts are reduced by the amount of fundraising contributions, per IRS instructions. The contributions for fiscal year 2024 were $33.7 million.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (55 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt
Albert Einstein College of Med Yeshiva U
1300 Morris Park AvenueBelfer 1108	Bronx	NY	104611975	131624225	501(c)(3)	$203,525	Research
Baptist Memorial Health Care Foundation
350 N Humphreys Blvd	Memphis	TN	38120	581544781	501(c)(3)	$93,730	Patient Care
Baylor College Medicine
One Baylor Plaza BCM 206	Houston	TX	770303411	741613878	501(c)(3)	$100,000	Research
Baylor University
One Bear Place 97043	Waco	TX	767987043	741159753	501(c)(3)	$59,924	Research
Boston University
580 Harrison Avenue 3-W	Boston	MA	02118	042103547	501(c)(3)	$179,998	Research
Brigham and Womens Hospital
181 Longwood Avenue 5th Floor	Boston	MA	02115	042312909	501(c)(3)	$80,000	Research
Case Western Reserve University
10900 Euclid Avenue	Cleveland	OH	441067006	341018992	501(c)(3)	$75,000	Research
Columbia University Medical Center
722 West 168th Street 4th Floor	New York	NY	100270000	135598093	501(c)(3)	$174,998	Research
Dana Farber Cancer Institute
44 Binney Street Mail Stop 439C	Boston	MA	10032	042263040	501(c)(3)	$105,000	Research
Dana-Farber Cancer Institute Inc
450 Brookline Avenue BP 412	Boston	MA	02115	042263040	501(c)(3)	$772,553	Research
Dana-Farber Cancer Institute
44 Binney Street Mail Stop 439C	Boston	MA	022155450	042263040	501(c)(3)	$774,685	Research
Duke University Medical Center
PO Box 602651	Charlotte	NC	02115	560532129	501(c)(3)	$460,284	Research
ECOG Research and Education Foundation
1818 Market Street	Philadelphia	PA	282602651	391723095	501(c)(3)	$75,530	Research
Emory University
1599 Clifton Road NE 4th Floor	Atlanta	GA	19109	580566256	501(c)(3)	$201,014	Research
Eskenazi Health
720 Eskenazi Avenue 5th Floor	Indianapolis	IN	303224250	356005697	501(c)(3)	$100,000	Patient Care
Houston Methodist Hospital
6445 Main Street OPC21-341	Houston	TX	46202	870721923	501(c)(3)	$45,000	Patient Care
Howard University
2041 Georgia Avenue NW	Washington	DC	77030	530204707	501(c)(3)	$48,750	Patient Care
Indiana U (Indianapolis)
PO Box 66057	Indianapolis	IN	20060	356001673	501(c)(3)	$586,012	Research
Indiana University (Indianapolis)
PO Box 66057	Indianapolis	IN	462666057	356001673	501(c)(3)	$436,311	Research
Johns Hopkins University
1650 Orleans Street	Baltimore	MD	462666057	520595110	501(c)(3)	$625,000	Research
Johns Hopkins U
1101 East 33rd Street Eastern C220	Baltimore	MD	21218	520595110	501(c)(3)	$452,282	Research
Leland Stanford Jr University
485 Broadway Mail Code 8838	Redwood City	CA	21231	941156365	501(c)(3)	$108,914	Research
Massachusetts Institute of Technology
160 Memorial Drive	Cambridge	MA	21218	042103594	501(c)(3)	$100,000	Research
Mayo Clinic Jacksonville
Griffin Building Room 170 4500 Sa	Jacksonville	FL	94063	593337028	501(c)(3)	$34,288	Research
Memorial Sloan-Kettering Cancer Ctr
633 Third Avenue 28th Floor	New York	NY	02139	131924236	501(c)(3)	$240,063	Research
Oregon Health & Science University
0690 SW Bancroft	Portland	OR	32224	931176109	501(c)(3)	$392,204	Research
Parkland Foundation
2777 North Stemmons Freeway	Dallas	TX	10017	752089180	501(c)(3)	$200,000	Research
Providence Portland Medical Center
PO Box 13993	Portland	OR	97239	930386906	501(c)(3)	$60,000	Research
Regents of University of Michigan
Room 7110 CCGC Internal Med	Ann Arbor	MI	75207	386006309	501(c)(3)	$75,000	Research
Roswell Park Alliance Foundation
Elm Carlton Streets	Buffalo	NY	97213	161391608	501(c)(3)	$150,000	Research
Stanford University
PO Box 44253	San Francisco	CA	481091274	941156365	501(c)(3)	$99,977	Research
Temple University
10th Floor Wachman Hall 038-17	Philadelphia	PA	14263	231365971	501(c)(3)	$75,000	Research
The Salk Institute
10010 North Torrey Pines Road	La Jolla	CA	941444253	952160097	501(c)(3)	$75,000	Research
The University of Chicago
970 East 58th Street 3rd Fl	Chicago	IL	19122	362177139	501(c)(3)	$356,283	Research
The University of Texas at Austin
300 W Dean Keeton A0900 BMC 2302	Austin	TX	920371002	746000203	501(c)(3)	$60,000	Research
The Wistar Institute
3601 Spruce Street	Philadelphia	PA	60637	236434390	501(c)(3)	$60,000	Research
Univ of North Carolina at Chapel Hill
104 Airport Drive Suite 2200 CB	Chapel Hill	NC	78712	566001393	501(c)(3)	$675,450	Research
Univ of Texas MD Anderson Cancer Center
PO Box 4390	Houston	TX	191044265	746001118	501(c)(3)	$170,000	Research
Universidad Central del Caribe
PO BOX 60327	Bayamon	PR	275991350	660349669	501(c)(3)	$58,300	Research
University of California at San Francis
3333 California St Suite 315	San Francisco	CA	772104390	946036493	501(c)(3)	$259,998	Research
University of Chicago
5801 S Ellis Ave	Chicago	IL	009606032	362177139	501(c)(3)	$220,000	Research
University of Houston
PO Box 988	Houston	TX	94118	746001399	501(c)(3)	$35,984	Research
University of Kansas Medical Center
3901 Rainbow Boulevard MSN 1039	Kansas City	KS	60637	481108830	501(c)(3)	$37,027	Research
University of North Carolina
104 Airport Drive Suite 2200 CB	Chapel Hill	NC	770010988	566001393	501(c)(3)	$100,000	Research
University of Pennsylvania
3451 Walnut Street P-211 Franklin	Philadelphia	PA	66160	231352685	501(c)(3)	$510,750	Research
University of Pittsburgh
3100 Cathedral of Learning	Pittsburgh	PA	275999525	250965591	501(c)(3)	$263,363	Research
University of Utah
201 South Presidents Circle Room	Salt Lake City	UT	191046205	876000525	501(c)(3)	$102,196	Research
University of Washington
3917 University Way NE	Seattle	WA	15260	916001537	501(c)(3)	$50,000	Research
University of Wisconsin - Madison
1440 Monroe Street	Madison	WI	841129020	396006492	501(c)(3)	$75,000	Research
UT Southwestern Medical Center
5323 Harry Hines Boulevard	Dallas	TX	98105	746000203	501(c)(3)	$150,000	Research
Vanderbilt University Medical Center
Dept AT 40303	Atlanta	GA	53711	620476822	501(c)(3)	$604,539	Research
Virginia Commonwealth University
800 E Leigh St Suite 3100	Richmond	VA	753909020	546001758	501(c)(3)	$59,857	Research
Washington University at St Louis Scho
660 S Euclid Ave Campus Box 8056	St Louis	MO	311920303	430653611	501(c)(3)	$249,286	Research
Weill Medical College of Cornell Univ
1300 York Avenue	New York	NY	232843039	131623978	501(c)(3)	$100,000	Research
Yale University
2 Whitney Avenue	New Haven	CT	63110	060646973	501(c)(3)	$250,000	Research

Field	Value	IRS element (for citing)
Total501c3 Org	55	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (2 entries)

Grant TypeGrantTypeTxt	RecipientRecipientCnt	Cash GrantCashGrantAmt
Patient Care Assistance @ $500	14151	$7,075,500
Patient Care Assistance @ $750	5105	$3,828,750

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds.	FormAndLineReferenceDesc
Explanation	SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT ARE MONITORED THROUGHOUT THE GRANT TERM BY A PH.D.-LEVEL RESEARCH GRANT MANAGER. FOR PATIENT CARE GRANTS, PROGRESS AND FINANCIAL OVERSIGHT ARE MONITORED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANT MANAGERS. AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR GRANTS, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. SEE SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Written Employment Contract	Yes (X)	WrittenEmploymentContractInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	false	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	false	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	false	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (12 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Eunice Nakamura
General Counsel and Corporate Secretary	$258,384	$0	$28,284	$0	$1,609	$0	$17,509	$0	$6,683	$0	$312,469	$0	$0	$0
Paula Schneider
President and CEO	$644,982	$0	$283,820	$0	$7,898	$0	$16,851	$0	$23,717	$0	$977,268	$0	$0	$0
Ria Williams
Chief Fin & Ops Officer	$304,817	$0	$32,825	$0	$2,093	$0	$19,359	$0	$28,874	$0	$387,968	$0	$0	$0
Catherine Olivieri
SVP, Human Resources	$251,890	$0	$28,325	$0	$4,604	$0	$17,244	$0	$13,977	$0	$316,040	$0	$0	$0
Sarah Rosales
VP, Corporate Partnerships	$244,223	$0	$19,741	$0	$1,353	$0	$15,006	$0	$17,336	$0	$297,659	$0	$0	$0
Victoria Smart
SVP, Mission	$301,131	$0	$32,819	$0	$2,580	$0	$15,385	$0	$6,366	$0	$358,281	$0	$0	$0
Kathryn Watt
VP, Marketing Strategy	$218,547	$0	$14,831	$0	$1,308	$0	$0	$0	$8,628	$0	$243,314	$0	$0	$0
Kim Sabelko
VP, Scientific Strategy & Programs	$195,388	$0	$16,068	$0	$1,606	$0	$12,181	$0	$11,762	$0	$237,005	$0	$0	$0
Kari Bodell
VP, Development Programs Strategy	$222,752	$0	$17,551	$0	$1,442	$0	$13,520	$0	$2,406	$0	$257,671	$0	$0	$0
Lori Maris
SVP, OPS SERVICES & SUPPORT	$186,049	$0	$17,630	$0	$1,637	$0	$9,233	$0	$6,634	$0	$221,183	$0	$0	$0
Catherine Stone
VP, Community Health	$199,601	$0	$16,000	$0	$1,400	$0	$12,420	$0	$2,389	$0	$231,810	$0	$0	$0
Rachel Davies
VP, Marketing & Communications	$179,172	$0	$13,562	$0	$1,258	$0	$10,801	$0	$4,682	$0	$209,475	$0	$0	$0

Schedule M IRS990ScheduleM

Food Inventory FoodInventoryGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	42	ContributionCnt
Noncash Contributions Rpt F990	$205,911	NoncashContributionsRptF990Amt
Method Of Determining Revenues	Market value	MethodOfDeterminingRevenuesTxt

Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)

Non Cash CheckboxNonCashCheckboxInd	DescDesc	ContributionContributionCnt	Noncash Contributions Rpt F990NoncashContributionsRptF990Amt	Method Of Determining RevenuesMethodOfDeterminingRevenuesTxt
Yes (X)	Gift bags/Gift Cards	56	$192,628	Market value
Yes (X)	Event Supplies	9	$12,652	Market value

Field	Value	IRS element (for citing)
Form8283 Received	1	Form8283ReceivedCnt
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	false	ReviewProcessUnusualNCGiftsInd
Third Parties Used	false	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule M, Part I Explanations of reporting method for number of contributions	FormAndLineReferenceDesc
Explanation	Food inventory - Food & Beverage Number of contributions Other - Gift bags/Gift Cards Number of contributions Other - Event Supplies Number of contributions	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (12 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Form 990, Part I, Line 6 VOLUNTEERS	VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE MORE THAN PINK WALKS, RACE FOR THE CURE RUNS, THE SUSAN G. KOMEN 3 DAY SERIES, AND ADVOCACY PROGRAMS.
Form 990, Part III, Line 4 Program service accomplishments	SUSAN G. KOMEN'S MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER. KOMEN TAKES A 360 DEGREE APPROACH TO FIGHT BREAST CANCER THROUGH: - RESEARCH, TO DRIVE BREAKTHROUGHS THAT WILL BRING US NEW KNOWLEDGE AND ADVANCES IN CARE FOR ALL. -COMMUNITY HEALTH, TO EMPOWER PEOPLE WITH TRUSTWORTHY INFORMATION AND SUPPORT PEOPLE IN THEIR BREAST HEALTH JOURNEY THROUGH DIRECT SERVICES, COMMUNITY PROGRAMS AND HEALTH SYSTEMS CHANGE. - AND PUBLIC POLICY, WHERE WE ADVOCATE FOR POLICIES TO CREATE SYSTEMIC AND LASTING CHANGES THAT WILL FUND AND FACILITATE RESEARCH AND ALLEVIATE THE BURDEN ON PATIENTS AND PROTECT ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE OF THE U.S. GOVERNMENT WHILE PROVIDING REAL-TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS INVESTED OVER $1.1 BILLION IN BREAST CANCER RESEARCH IN MORE THAN 2800 GRANTS AND MORE THAN 500 CLINICAL TRIALS CONDUCTED BY THOUSANDS OF THE BEST AND BRIGHTEST RESEARCHERS ACROSS THE US AND AROUND THE WORLD. KOMEN HAS ALSO PROVIDED OVER $3.3 BILLION IN COMMUNITY INVESTMENT FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION, AND EMOTIONAL PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE AS WELL AS PUBLIC POLICY AND ADVOCACY EFFORTS AT THE FEDERAL, STATE, AND LOCAL LEVELS, EMPOWERING POLICYMAKERS WITH KNOWLEDGE TO ACT FOR LASTING, SYSTEMIC CHANGE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. KOMEN REMAINS COMMITTED TO SUPPORTING THOSE AFFECTED BY BREAST CANCER TODAY, WHILE TIRELESSLY SEARCHING FOR TOMORROW'S CURES. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. AND WE HAVE A BETTER UNDERSTANDING OF THE MANY FACTORS CONTRIBUTING TO DISPARITIES IN BREAST CANCER CARE AND OUTCOMES AND HOW TO ADDRESS/ELIMINATE THEM, WHICH ARE ESSENTIAL STEPS ON THE PATH TO HEALTH EQUITY. KOMEN'S RESEARCH PROGRAMS ARE ADDRESSING CRITICAL ISSUES AND CUTTING-EDGE TOPICS THAT WILL DRIVE PROGRESS TOWARDS BREAST CANCER AND PROVIDE THE GREATEST BENEFIT TO PATIENTS. THE PATIENT VOICE IS CENTRAL TO OUR WORK AS WE ASK BIG QUESTIONS AND SEEK OUT THE ANSWERS THAT WILL SAVE LIVES AND END BREAST CANCER FOREVER. WE LEAN ON OUR SCIENTIFIC EXPERTISE AND PATIENT INSIGHTS TO INFLUENCE THE STRATEGY, DESIGN AND CONDUCT OF RESEARCH; TO INVEST IN SCIENCE AND TECHNOLOGY AND SUPPORT THE NEXT GENERATION OF DIVERSE RESEARCH LEADERS, AND TO CONDUCT OUR OWN RESEARCH THAT'S ENGAGING DIVERSE, REAL-WORLD PEOPLE AS OUR PARTNERS IN RESEARCH AND CONTRIBUTING TO THE BODY OF EVIDENCE ABOUT BREAST CANCER. WITH OUR OVER $1.1 BILLION RESEARCH INVESTMENT, KOMEN IS SUPPORTING LABORATORY RESEARCH, TRANSLATIONAL STUDIES, POPULATION SCIENCE AND CLINICAL TRIALS THAT ARE PAVING THE ROAD WITH SCIENTIFIC DISCOVERIES THAT ARE: - UNRAVELLING THE BIOLOGY OF BREAST CANCER, INCLUDING AGGRESSIVE & METASTATIC BREAST CANCERS - LEADING TO THE DEVELOPMENT OF NEW BREAST CANCER DRUGS AND NEW TECHNOLOGIES AND TESTS, - CHANGING THE STANDARD OF BREAST CANCER CARE AND -ADVANCING PERSONALIZED, PRECISION CARE FOCUSED ON THE PERSON AND THEIR BREAST CANCER PROVIDING NEW, EVIDENCE-BASED INTERVENTIONS TO IMPROVE THE DELIVERY OF THAT CARE. OUR GOAL IS TO IMPROVE HEALTH OUTCOMES FOR EVERYONE AND SAVE LIVES. KOMEN HAS HAD MORE THAN 4,100 RESEARCH DISCOVERIES THAT ARE MOVING US CLOSER TO THAT GOAL. THIS INCLUDES OVER 900 NEW DISCOVERIES FOCUSED ON METASTATIC BREAST CANCER, MORE THAN 1,800 POTENTIAL TREATMENTS AND NEARLY 600 NEW STRATEGIES TO ELIMINATE BREAST CANCER DISPARITIES. THEY INCLUDE ADVCANCES SUCH AS NEW BIOMARKERS, NEW DRUG TARGETS, NEW TREATMENTS, AND NEW HEALTH CARE DELIVERY TOOLS. IN PAVING THIS ROAD WITH SCIENTIFIC DISCOVERIES, WE'RE ALSO PAVING IT WITH HOPE. THE HOPE THAT NEW WAYS TO DETECT, DIAGNOSE, TREAT, PREVENT AND, ULTIMATELY, CURE BREAST CANCER ARE AROUND THE CORNER AND THERE WHEN PEOPLE WITH BREAST CANCER NEED THEM TO ALLOW THEM TO LIVE LONGER, WITH IMPROVED QUALITY OF LIFE. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY MORE THAN 50 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. TOGETHER, THIS EXCLUSIVE GROUP OF BREAST CANCER RESEARCHERS, CLINICIANS AND ADVOCATES HELP GUIDE THE ORGANIZATION'S WORK TO SAVE LIVES AND END BREAST CANCER. KOMEN'S TEAM OF HIGHLY QUALIFIED PROFESSIONALS INCLUDING THOSE WITH PHD-LEVEL EXPERTISE DEVELOP AND IMPLEMENT KOMEN-LED, PATIENT CENTRIC RESEARCH & SCIENTIFIC PROGRAMS CREATED TO FILL CRITICAL GAPS IN THE SYSTEM AND DRIVE PROGRESS IN UNDERSTUDIED TOPICS AND EMERGING ISSUES IN BREAST CANCER. THE INFLAMMATORY BREAST CANCER (IBC) COLLABORATIVE, BIG DATA FOR BREAST CANCER (BD4BC) AND SHAREFORCURES ARE EXAMPLES OF THE INNOVATIVE AND IMPACTFUL KOMEN-LED PROGRAMS ACTIVE IN FY24. INFLAMMATORY BREAST CANCER (IBC) COLLABORATIVE IN 2016, KOMEN PARTNERED WITH THE INFLAMMATORY BREAST CANCER RESEARCH FOUNDATION AND THE MILBURN FOUNDATION TO LEAD THIS COLLABORATIVE GROUP FOCUSED ON ACCELERATING IBC RESEARCH AND IMPROVING CARE AND OUTCOMES FOR PEOPLE WITH IBC, A DEADLY AND AGGRESSIVE FORM OF CANCER. KOMEN CONVENED PATIENT ADVOCATES, BREAST CANCER RESEARCHERS AND CLINICIANS TO REVIEW THE STATE OF IBC CARE AND RESEARCH GLOBALLY AND PROPOSE SPECIFIC INITIATIVES TO MOVE THE FIELD FORWARD. THE OUTCOME OF THE DISCUSSIONS WAS ABUNDANTLY CLEAR: THE FIELD NEEDS A FORMAL DEFINITION OF IBC. WITHOUT A CLEAR DEFINITION, BOTH PATIENT CARE AND RESEARCH SUFFER. DIAGNOSIS REMAINS SUBJECTIVE AND TREATMENT VARIABLE. THE GOAL IS TO MOVE BEYOND THE SUBJECTIVE 'CLINICAL DIAGNOSIS' TO A SET OF SPECIFIC DIAGNOSTIC CRITERIA AND SCORING SYSTEM THAT WILL ADVANCE IBC RESEARCH AND FACILITATE THE DISCOVERIES THAT WILL IMPROVE THE CARE OF IBC PATIENTS. THE COLLABORATIVE PUBLISHED A PROPOSED DEFINITION OF IBC, BASED ON A REVIEW OF CLINICAL, AND PATHOLOGIC FEATURES IN 2022. THIS EVIDENCE-BASED SCORING SYSTEM IS CURRENTLY BEING VALIDATED (A CRITICAL STEP FOR IT TO BE WIDELY ADOPTED) BY KOMEN-FUNDED RESEARCHERS AT TWO OF THE WORLD'S LEADING IBC CLINICS. IN FY24 KOMEN CREATED AN EASY-TO-USE IBC SCORING SYSTEM ONLINE TOOL TO HELP DOCTORS DIAGNOSE IBC ACCURATELY AND EARLIER. BIG DATA FOR BREAST CANCER KOMEN CONTINUES WORK ON THE BIG DATA FOR BREAST CANCER INITIATIVE, WHICH IS AIMED AT USING BIG DATA TO FUEL SCIENTIFIC DISCOVERIES AND ACCELERATE THE DELIVERY OF EQUITABLE, PATIENT-FOCUSED CARE. KOMEN EMPOWERS BREAST CANCER PATIENTS, ADVOCATES, AND THE PUBLIC WITH INFORMATION AND TOOLS TO MAKE DATA SHARING UNDERSTANDABLE THROUGH THE BIG DATA FOR PATIENTS EDUCATIONAL PROGRAMS. WE ALSO ADDRESS THE CHALLENGES OF INCORPORATING BIG DATA APPLICATIONS INTO BREAST CANCER RESEARCH AND CLINICAL CARE THROUGH WORKING WITH PARTNERS REPRESENTING A VARIETY OF STAKEHOLDERS IN BREAST CANCER RESEARCH AND CLINICAL CARE. ADDITIONALLY, KOMEN SUPPORTS DATA SCIENCE PROJECTS TO IMPROVE BREAST CANCER OUTCOMES AND SAVE LIVES, SUCH AS THE BREAST CANCER HACKATHON CHALLENGE AND KOMEN'S PEOPLE-POWERED BREAST CANCER RESEARCH REGISTRY, SHAREFORCURES. LAUNCHED IN JULY 2023, SHAREFORCURES BUILDS ON KOMEN'S COMMITMENT TO DELIVER THE PROMISE OF BIG DATA TO BREAST CANCER PATIENTS. THIS INVALUABLE BREAST CANCER REGISTRY LEVERAGES THE LATEST TECHNOLOGY AND KOMEN'S BROAD, NATIONAL REACH TO DIRECTLY ENGAGE WITH INDIVIDUALS IMPACTED BY BREAST CANCER WHILE PROVIDING A SAFE, SECURE PATHWAY FOR PEOPLE FROM DIVERSE BACKGROUNDS TO SHARE THEIR HEALTH DATA AND PARTICIPATE IN BREAST CANCER RESEARCH. WITH THIS ROBUST DATA PROVIDED DIRECTLY BY PATIENTS, KOMEN WILL BREAK DOWN SILOS, FUEL SCIENTIFIC DISCOVERIES AND ACCELERATE THE DELIVERY OF EQUITABLE, PATIENT-FOCUSED CARE.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	KOMEN ALSO AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND INSTITUTIONS THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY24, KOMEN AWARDED 32 GRANTS TO SUPPORT CUTTING-EDGE, IMPACTFUL SCIENTIFIC RESEARCH, IN THE UNITED STATES AND ITS TERRITORIES. MOST OF THE GRANTS AWARDED THIS YEAR SUPPORT OUTSTANDING RESEARCH PROJECTS BEING CONDUCTED BY A DIVERSE GROUP OF EARLY CAREER RESEARCHERS, THE NEXT GENERATION OF LEADERS WHO WILL MAKE BREAKTHROUGHS DISCOVERIES AND INNOVATIONS TO END BREAST CANCER. NEW IN FY24, THE SUSAN G. KOMEN CAREER TRANSITION AWARDS (CTA) AIM TO HELP OUTSTANDING SENIOR POSTDOCTORAL FELLOWS AND CLINICAL FELLOWS WORKING UNDER THE GUIDANCE OF A MENTOR TO LAUNCH COMPETITIVE, INDEPENDENT RESEARCH CAREERS IN BREAST CANCER. THE CTAS PROVIDE UP TO FIVE YEARS OF RESEARCH FUNDING IN TWO PHASES: PHASE 1 SUPPORTS THE FINAL YEARS OF MENTORED, POSTDOCTORAL TRAINING AND PHASE 2 SUPPORTS THE INDEPENDENT BREAST CANCER-FOCUSED RESEARCH OF THE EARLY CAREER, TENURE-TRACK INVESTIGATORS. WITH THE ASPIRE GRANTS (A SUPPLEMENT TO PROMOTE INCLUSION FOR RESEARCH EXCELLENCE) KOMEN SEEKS TO ENHANCE THE DIVERSITY OF THE BREAST CANCER RESEARCH WORKFORCE BY PROVIDING ESTABLISHED BREAST CANCER SCIENTISTS WITH SUPPLEMENTAL FUNDING FOR UP TO TWO YEARS TO SUPPORT RESEARCH TRAINEES FROM COMMUNITIES HISTORICALLY MINORITIZED AND MARGINALIZED IN RESEARC AND UNDERREPRESENTED IN THE RESEARCH WORKFORCE. LEADERSHIP GRANTS SUPPORT KOMEN SCIENTIFIC ADVISORS PURSUING INNOVATIVE RESEARCH PROJECTS WHICH WILL IMPROVE THE UNDERSTANDING, DETECTION, TREATMENT OR PREVENTION OF BREAST CANCER, WITH A FOCUS ON CONQUERING METASTATIC BREAST CANCER, ADVANCING PRECISION MEDICINE AND ELIMINATING BREAST CANCER DISPARITIES. THIS YEAR OPPORTUNITY GRANTS WERE AWARDED TO TWO OF THE HACKATHON PARTICIPANTS TO BUILD ON THE WORK THEY STARTED AT THE 2023 EVENT. THE 32 RESEARCH GRANTS AWARDED IN FY24 ARE: CAREER TRANSITION AWARDS: MORIAH BELLISSIMO, PH.D., FROM VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE, WILL INVESTIGATE WHETHER SHORT PERIODS OF INTENSE EXERCISE CAN PREVENT HEART PROBLEMS FOR PATIENTS WHO RECEIVED CHEMOTHERAPY FOR BREAST CANCER. BY PARTICIPATING IN PHYSICAL EXERCISE DURING THEIR TREATMENT, THESE PATIENTS CAN PREVENT HEART PROBLEMS ASSOCIATED WITH CHEMOTHERAPY AND EXPERIENCE A HIGHER QUALITY OF LIFE. KRISTEN BRANTLEY, PH.D., FROM DANA-FARBER CANCER INSTITUTE, IS STUDYING HOW INHERITED GENE MUTATIONS AND TUMOR MUTATIONS IMPACT BREAST CANCER PROGNOSIS IN YOUNG WOMEN. THE GOAL OF THIS STUDY IS TO BETTER UNDERSTAND THE UNDERLYING BIOLOGY OF BREAST CANCERS FOUND IN YOUNG WOMEN TO FURTHER PERSONALIZE THEIR TREATMENT AND MONITORING. DOUGLAS FOX, PH.D., FROM MASSACHUSETTS GENERAL HOSPITAL, WILL STUDY HOW ETS PROTEINS CONTRIBUTE TO HORMONE THERAPY RESISTANCE IN HORMONE RECEPTOR-POSITIVE BREAST CANCER. IF ETS PROTEINS ARE REQUIRED FOR HORMONE THERAPY RESISTANCE, NEW THERAPIES CAN BE DEVELOPED TO TARGET ETS PROTEINS AND RESTORE SENSITIVITY TO HORMONE THERAPY. SITING GAN, PH.D., FROM MEMORIAL SLOAN KETTERING CANCER CENTER, WILL INVESTIGATE HOW METASTATIC BREAST TUMOR CELLS INTERACT WITH SURROUNDING BRAIN TISSUE TO PROMOTE BRAIN METASTASIS. THESE STUDIES WILL GUIDE THE DEVELOPMENT OF NEW TREATMENTS FOR BREAST CANCER BRAIN METASTASIS. EMANUELA MARCHESE, PH.D., FROM MASSACHUSETTS GENERAL HOSPITAL, WILL INVESTIGATE HOW THE IMMUNE SYSTEM CAN HELP PREVENT BREAST CANCER FROM FORMING IN BRCA MUTATION CARRIERS. THE GOAL OF THIS RESEARCH IS TO DEVELOP NEW THERAPEUTIC STRATEGIES FOR BREAST CANCER PREVENTION WHICH CAN ULTIMATELY BENEFIT PATIENTS AT HIGH RISK OF DEVELOPING BREAST CANCER. JUN NISHIDA, PH.D., FROM DANA-FARBER CANCER INSTITUTE, WILL STUDY HOW A PROTEIN IN BREAST CANCER CELLS CALLED KDM2A ALLOWS BREAST CANCER TO SURVIVE IN THE LOW-NUTRIENT ENVIRONMENT OF THE BRAIN. DR. NISHIDA PROPOSES THAT TARGETING KDM2A MAY BE AN EFFECTIVE WAY TO TREAT BREAST CANCER BRAIN METASTASES. LONG NGUYEN, M.D., PH.D., FROM THE UNIVERSITY OF CHICAGO, IS STUDYING HOW A PROTEIN CALLED BACH1 REDUCES THE RESPONSE TO IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER. THE GOAL OF THE STUDY IS TO DETERMINE WHETHER TARGETING BACH1 CAN IMPROVE IMMUNOTHERAPY TREATMENT OUTCOMES FOR PEOPLE WITH TRIPLE NEGATIVE BREAST CANCER. PURAB PAL, PH.D., FROM THE UNIVERSITY OF ILLINOIS AT CHICAGO, WILL INVESTIGATE HOW A TYPE OF FAT MOLECULE CALLED CERAMIDES CAN SPECIFICALLY KILL HORMONE THERAPY-RESISTANT BREAST CANCER CELLS. THE GOAL OF THIS PROJECT IS TO FIND A NEW THERAPEUTIC STRATEGY FOR HORMONE THERAPY RESISTANT, HORMONE RECEPTOR-POSITIVE BREAST CANCER. NOLAN PRIEDIGKEIT, M.D., PH.D., FROM DANA-FARBER CANCER INSTITUTE, IS STUDYING THE ROLE OF MOLECULES CALLED FUSION RNAS IN METASTATIC BREAST CANCER. DR. PRIEDIGKEIT WILL TEST A NEW TECHNOLOGY THAT CAN TARGET FUSION RNAS AND USE THESE FUSION RNAS AS A TOOL TO KILL CANCER CELLS FROM WITHIN. THE GOAL OF THIS PROJECT IS TO DEVELOP A BREAKTHROUGH FUSION RNA-BASED THERAPEUTIC FOR PATIENTS WITH ADVANCED BREAST CANCER. YIFAN WANG, PH.D., FROM UT M.D. ANDERSON CANCER CENTER, WILL INVESTIGATE HOW ANTIGEN PRESENTATION, OR HOW CANCER CELLS REVEAL THEMSELVES TO IMMUNE CELLS, CAN BE ACTIVATED IN BREAST CANCER CELLS TO INCREASE THE EFFECTIVENESS OF IMMUNOTHERAPY. THE GOAL OF THE STUDY IS TO IDENTIFY A NEW IMMUNOTHERAPEUTIC STRATEGY FOR BREAST CANCER. ASPIRE GRANTS: ERAN ANDRECHEK, PH.D., FROM MICHIGAN STATE UNIVERSITY, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT JESUS GARCIA-LERENA, WHO IS STUDYING THE ROLE OF A PROTEIN CALLED E2F5 IN BREAST CANCER METASTASIS TO THE LIVER AND LYMPH NODES. THE GOAL OF THIS STUDY IS TO BETTER UNDERSTAND THIS MECHANISM, WHICH COULD HELP UNCOVER POTENTIAL NEW THERAPEUTIC OPTIONS TO PREVENT BREAST CANCER METASTASIS. PAULA BOS, PH.D., FROM THE VIRGINIA COMMONWEALTH UNIVERSITY, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT AILEN GARCIA-SANTILLAN, WHO IS STUDYING HOW IMMUNE CELLS AND NEURONS IN THE BRAIN IMPACT BREAST CANCER BRAIN METASTASIS. LEARNING MORE ABOUT THIS RELATIONSHIP COULD HELP US FIND NEW WAYS TO TREAT BRAIN METASTASIS. EIDA CASTRO, PSY.D., M.SC., FROM PONCE MEDICAL SCHOOL FOUNDATION IN PUERTO RICO, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT LIANEL ROSARIO, WHO IS ADDRESSING THE LIMITED SOCIAL-SUPPORT SERVICES AND PSYCHO-ONCOLOGY MENTAL HEALTH CARE AVAILABLE FOR HISPANIC BREAST CANCER SURVIVORS IN PUERTO RICO. TOGETHER, THEY WILL CONDUCT A CLINICAL TRIAL TO DETERMINE WHETHER IMPROVING PATIENTS' ACCESS TO MENTAL HEALTH CARE AFFECTS CERTAIN BIOLOGICAL MARKERS OF STRESS, WHICH MIGHT HAVE AN IMPACT ON BREAST CANCER OUTCOMES. ISAAC CHAN, M.D., PH.D., FROM THE UNIVERSITY OF TEXAS SOUTHWESTERN, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT ISABELLA TERRAZAS, WHO IS INVESTIGATING THE ROLE OF A TYPE OF IMMUNE CELLS CALLED NATURAL KILLER CELLS DURING IMMUNOTHERAPY TREATMENT. FURTHERING OUR UNDERSTANDING OF NATURAL KILLER CELLS MAY PAVE THE WAY FOR DEVELOPING NEW BREAST CANCER IMMUNOTHERAPIES THAT TARGET NATURAL KILLER CELLS. SURANGANIE DHARMAWARDHANE, PH.D., FROM THE UNIVERSITY OF PUERTO RICO, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER AILED CRUZ-COLLAZO, PH.D., WHO IS INVESTIGATING THE NEW DRUG MBQ-167 AS A POTENTIAL THERAPY FOR TRIPLE NEGATIVE BREAST CANCER AND METASTASIS. THE GOAL OF THIS STUDY IS TO PROVIDE PRECLINICAL DATA FOR THIS DRUG THAT LEADS TO THE INITIATION OF A PHASE 1 CLINICAL TRIAL INVESTIGATING ITS USE IN ADVANCED BREAST CANCERS. STEPHANIE FRALEY, PH.D., FROM THE UNIVERSITY OF CALIFORNIA SAN DIEGO, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT MAYA ROWELL, WHO IS STUDYING HOW A PROTEIN FOUND OUTSIDE OF BREAST CANCER CELLS CALLED COL1 PROMOTES BREAST CANCER METASTASIS. THE GOAL OF THE STUDY IS TO IDENTIFY POTENTIAL THERAPEUTIC STRATEGIES TO PREVENT METASTASIS CAUSED BY COL1. AIMILIA GASTOUNIOTI, PH.D., AT WASHINGTON UNIVERSITY IN ST. LOUIS, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR FOR POSTDOCTORAL TRAINEE JUANITA HERNANDEZ, PH.D., WHO IS USING ARTIFICIAL INTELLIGENCE TO IDENTIFY BLACK WOMEN THAT ARE AT A HIGH AND LOW RISK FOR DEVELOPING BREAST CANCER. THE GOAL OF THE STUDY IS TO DEVELOP A BREAST CANCER RISK ASSESSMENT TOOL THAT CAN BE USED TO PERSONALIZE TREATMENTS, AND ULTIMATELY, REDUCE BREAST CANCER MORTALITY AMONG BLACK WOMEN. CHRISTY HAGAN, PH.D., FROM UNIVERSITY OF KANSAS, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR FOR GRADUATE STUDENT JULIO TINOCO, WHO IS INVESTIGATING WHETHER TARGETING THE PROGESTERONE RECEPTOR CAN PREVENT SUPPRESSION OF THE IMMUNE SYSTEM IN PROGESTERONE RECEPTOR-POSITIVE BREAST TUMORS. THE GOAL OF THIS STUDY IS TO UNCOVER A NEW WAY TO PREVENT AND TREAT PROGESTERONE RECEPTOR-POSITIVE BREAST CANCER.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	KEVIN JANES, PH.D., FROM THE UNIVERSITY OF VIRGINIA, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT CATALINA ALVAREZ YELA, WHO IS STUDYING HOW ERRORS IN THE CELL CYCLE OCCUR IN TRIPLE NEGATIVE BREAST CANCER CELLS THAT LEAD TO CHROMOSOMAL IMBALANCE. THE GOAL OF THIS PROJECT IS TO GAIN A BETTER UNDERSTANDING OF THIS PROCESS AND IDENTIFY NEW THERAPIES THAT CAN REVERSE IT. ANNE MARIE MCCARTHY, PH.D., SC.M., FROM THE UNIVERSITY OF PENNSYLVANIA, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT MATTIA MAHMOUD WHO IS EVALUATING A NEW BIOMARKER ASSOCIATED WITH BREAST CANCER RISK CALLED BACKGROUND PARENCHYMAL ENHANCEMENT (BPE). BPE IS A PHENOMENON THAT OCCURS WHEN SOME WOMEN UNDERGO AN MRI SCAN, AND THIS STUDY WILL BE THE FIRST TO ASSESS BPE AS A BIOMARKER OF BREAST CANCER RISK IN BLACK WOMEN. HEATHER NEUMAN, M.D., FROM THE UNIVERSITY OF WISCONSIN-MADISON, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR FOR POSTDOCTORAL TRAINEE FAITH DICKERSON, PH.D., WHO IS DEVELOPING A CONVERSATION GUIDE FOR BREAST SURGEONS TO DISCUSS TREATMENT OPTIONS WITH PATIENTS OF DIVERSE BACKGROUNDS. THE GOAL OF THIS GUIDE IS TO HELP SURGEONS BETTER SUPPORT PATIENTS' NEEDS AS THEY DISCUSS SURGICAL OPTIONS LIKE BREAST RECONSTRUCTION WITH THEM. JULIE PALMER, SC.D., FROM BOSTON UNIVERSITY, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL RESEARCHER ETIENNE X. HOLDER, PH.D., WHO IS STUDYING HOW STRESS INDUCED BY THE NEIGHBORHOOD A PERSON LIVES IN CAN IMPACT BREAST CANCER OUTCOMES. THE GOAL OF THIS RESEARCH IS TO UNDERSTAND WHY BLACK WOMEN FACE A DISPROPORTIONATELY HIGH BREAST CANCER MORTALITY RATE AND DETERMINE IF STRESS-REDUCING INTERVENTIONS CAN IMPROVE OUTCOMES. WESTON PORTER, PH.D., FROM TEXAS A&M UNIVERSITY, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT HANNAH CARTER, WHO IS STUDYING HOW A PROTEIN CALLED SIM2 REGULATES MITOCHONDRIA TO MAINTAIN THE METABOLISM OF ESTROGEN RECEPTOR-POSITIVE BREAST CANCER CELLS. THE GOAL OF THIS PROJECT IS TO BETTER UNDERSTAND HOW ESTROGEN RECEPTOR-POSITIVE BREAST CANCERS MAINTAIN THEIR METABOLIC STATE, WHICH COULD LEAD TO THE FUTURE DEVELOPMENT OF NEW THERAPIES THAT WILL DISRUPT THEIR PROGRESSION AND KILL THEM. JEFF ROSEN, PH.D., FROM BAYLOR COLLEGE OF MEDICINE, WILL SERVE AS MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT ALEX SMITH, WHO IS STUDYING THE ROLE OF A TYPE OF IMMUNE CELL CALLED TUMOR-ASSOCIATED MACROPHAGE IN TRIPLE NEGATIVE BREAST CANCER. THE GOAL OF THE STUDY IS TO IDENTIFY WAYS TO TARGET TUMOR-ASSOCIATED MACROPHAGES TO IMPROVE OUTCOMES FOR PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER. SOHAIL TAVAZOIE, M.D., PH.D., FROM THE ROCKEFELLER UNIVERSITY, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL FELLOW KING FAISAL YAMBIRE, PH.D., WHO IS STUDYING THE ROLE OF A NEWLY DISCOVERED TYPE OF RNA CALLED MITOCHONDRIAL TRNA IN BREAST CANCER METASTASIS. THE GOAL OF THIS STUDY IS TO IDENTIFY HOW MITOCHONDRIAL TRNAS IMPACT BREAST CANCER METASTASIS AND DETERMINE IF THEY COULD BE EFFECTIVE TARGETS FOR NEW BREAST CANCER TREATMENTS. HAI WANG, PH.D., FROM ROSWELL PARK CANCER INSTITUTE, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT GRADUATE STUDENT CHEYENNE ERNST, WHO IS STUDYING HOW BREAST CANCER CELLS CHANGE THEIR METABOLISM TO ADAPT TO THEIR NEW ENVIRONMENT DURING METASTASIS, SPECIFICALLY IN THE BONE. THE GOAL OF THIS STUDY IS TO IDENTIFY WAYS TO BLOCK THIS ADAPTATION TO PREVENT BONE METASTASIS. ALANA WELM, PH.D., FROM THE UNIVERSITY OF UTAH, WILL SERVE AS THE MENTOR AND PRINCIPAL INVESTIGATOR TO SUPPORT POSTDOCTORAL FELLOW ZANNEL BLANCHARD, PH.D., WHO IS STUDYING HOW BREAST CANCER EVOLVES IN RESPONSE TO TREATMENT. THE GOAL OF THE STUDY IS TO BETTER UNDERSTAND HOW CERTAIN FACTORS MAKE BREAST CANCER MORE RESISTANT TO TREATMENT. LEADERSHIP GRANTS: KOMEN SCHOLAR LISA COUSSENS, PH.D., OF OREGON HEALTH & SCIENCE UNIVERSITY, WILL INVESTIGATE NEW WAYS OF USING THE IMMUNE SYSTEM TO ATTACK BREAST CANCER CELLS. THE GOAL OF THIS RESEARCH IS TO APPLY IMMUNOTHERAPY TREATMENTS TO MORE PATIENTS, AS NOT ALL PEOPLE WITH BREAST CANCER BENEFIT FROM CURRENTLY AVAILABLE IMMUNOTHERAPIES. KOMEN SCHOLAR CHRISTINA CURTIS, PH.D., OF STANFORD UNIVERSITY, WILL USE ADVANCED COMPUTATIONAL TECHNIQUES TO EXPLAIN HOW A BREAST TUMOR'S SURROUNDINGS IMPACT ITS PROGRESSION IN HIGH-RISK, EARLY-STAGE BREAST CANCER. THE GOAL OF THE PROJECT IS TO IDENTIFY WAYS TO REDUCE THE RISK OF RECURRENCE FOR THE 20-30% OF PATIENTS WHO DIE OF RECURRENT BREAST CANCER. KOMEN SCHOLAR MELISSA TROESTER, PH.D., FROM THE UNIVERSITY OF NORTH CAROLINA CHAPEL HILL, WILL EVALUATE TUMOR AND DNA SAMPLES FROM THE CAROLINA BREAST CANCER STUDY TO DETERMINE HOW THE COMPOSITION OF IMMUNE CELLS DIFFERS BETWEEN AFRICAN AMERICAN AND WHITE WOMEN. THE GOAL OF THIS PROJECT IS TO BETTER UNDERSTAND HOW VARIATIONS WITHIN THE TUMORS OF AFRICAN AMERICAN WOMEN CONTRIBUTES TO RACIAL DISPARITIES IN BREAST CANCER OUTCOMES AND RECURRENCE. OPPORTUNITY GRANTS: XIN LU, PH.D., OF THE UNIVERSITY OF NOTRE DAME, WILL DEVELOP A COMPUTATIONAL MODEL OF BREAST CANCER TUMOR METABOLISM TO IDENTIFY MOLECULES THAT REGULATE A SPECIFIC POPULATION OF IMMUNE CELLS, WHICH ARE ONLY EXPRESSED IN TUMORS AND ARE KNOWN TO DRIVE DISEASE PROGRESSION. IDENTIFIED MOLECULES WILL BE TESTED IN CELL LINES AND ANIMAL MODELS AS POTENTIAL NEW IMMUNOTHERAPEUTIC TARGETS. HARIKRISHNA NAKSHATRI, PH.D., FROM INDIANA UNIVERSITY, WILL DETERMINE THE FUNCTIONAL ROLES OF TWO NEWLY IDENTIFIED MOLECULES THAT ACCOMPANY A COMMON MUTATION IN BREAST CANCER AND MAY WORK TOGETHER TO DRIVE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER. COMPUTATIONAL APPROACHES WILL BE USED TO IDENTIFY ADDITIONAL MOLECULES AND THEIR POTENTIAL AS NEW THERAPEUTIC TARGETS. EDUCATION KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, INTERACTIVE 3D MODELS, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE ABOUT BREAST CANCER AND PORTIONS OF THE PATIENT & CAREGIVER SECTIONS OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER/HARVARD CANCER CENTER STAFF, RECEIVED MORE THAN 2.5 MILLION USERS DURING FY24. WHETHER A NEW THERAPY OR TEST BECOMES PART OF THE STANDARD OF CARE FOR BREAST CANCER DEPENDS LARGELY ON CLINICAL TRIAL RESULTS. KOMEN USED THE CLINICAL TRIALS EDUCATION INITIATIVE ON KOMEN.ORG TO EDUCATE PEOPLE ABOUT THE IMPORTANCE OF CLINICAL TRIALS AND THE NEED FOR DIVERSITY OF STUDY PARTICIPANTS, INCLUDING THOSE FROM POPULATIONS UNDER- REPRESENTED IN CLINICAL RESEARCH STUDIES, AND TO EMPOWER PEOPLE WITH INFORMATION ON TRIALS AND RESOURCES, WITH PERSONALIZED SUPPORT AVAILABLE THROUGH THE KOMEN BREAST CARE HELPLINE. THE RESOURCES HELP TO ENSURE PATIENTS ARE EQUIPPED TO MAKE INFORMED DECISIONS REGARDING TRIAL PARTICIPATION IN PARTNERSHIP WITH THEIR HEALTH CARE PROVIDERS. THE INITIATIVE ALSO RAISES AWARENESS OF THE DIFFERENT TYPES OF TRIALS, INCLUDING TRIALS SUPPORTED BY KOMEN FOCUSED ON RISK, SCREENING AND EARLY DETECTION, TREATMENT, FAMILY SUPPORT, QUALITY OF LIFE AND SURVIVORSHIP. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE RESOURCES IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACT SHEETS, AND C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS. IN ADDITION, IN FY24 KOMEN CONTINUED TO SUPPORT THE METASTATIC BREAST CANCER (MBC) COMMUNITY BY HOSTING 12 VIRTUAL EVENTS THROUGH THE MBC IMPACT SERIES. THESE EVENTS PROVIDED PEOPLE LIVING WITH METASTATIC BREAST CANCER AND THEIR LOVED ONES A SAFE, COLLABORATIVE SPACE TO GATHER INFORMATION AND DISCOVER PRACTICAL RESOURCES TO HELP MAKE DECISIONS FOR IMPROVED PHYSICAL AND EMOTIONAL HEALTH. WE OFFER ON-DEMAND VIDEOS OF THESE EVENTS IN BOTH ENGLISH AND SPANISH FOR THOSE NOT ABLE TO ATTEND LIVE. THE MBC IMPACT SERIES ALSO OFFERS REGULAR NEWSLETTERS AND QUARTERLY WELLNESS WEDNESDAY VIDEOS FOCUSED ON QUALITY OF LIFE AND OVERALL WELLNESS TOPICS.
Form 990, Part III, Line 4 PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	PATIENT SUPPORT KOMEN IS COMMITTED TO ELIMINATING BREAST HEALTH DISPARITIES AND ENSURING ALL PEOPLE HAVE ACCESS TO THE HIGH-QUALITY CARE THEY NEED. THROUGHOUT OUR HISTORY, WE HAVE HELPED REMOVE FINANCIAL, GEOGRAPHIC, AND CULTURAL BARRIERS TO CARE, AND WE CONTINUE TO EVOLVE OUR PATIENT CARE MODEL TO MEET THE NEEDS OF BREAST CANCER PATIENTS TODAY. THE KOMEN PATIENT CARE CENTER (PCC) PROVIDES INDIVIDUALIZED, DIRECT PATIENT CARE AND SUPPORT ACROSS THE BREAST HEALTH CONTINUUM THROUGH A NATIONAL TELEHEALTH MODEL. KOMEN'S TEAM OF PATIENT NAVIGATORS ARE THE ENGINE BEHIND OUR PATIENT CARE CENTER. OUR PATIENT NAVIGATORS, WHO ARE INFORMED BY EVIDENCE-BASED INTERVENTIONS, HELP BREAK DOWN BARRIERS TO CARE BY GUIDING PATIENTS THROUGH NUMEROUS DECISIONS, APPOINTMENTS AND TREATMENT OPTIONS. THEY STAY WITH PATIENTS FOR AS LONG AS NEEDED, FROM DAYS TO MONTHS, ENSURING ALL PATIENTS HAVE ACCESS TO THE RESOURCES AND CARE THEY NEED. ACCESSED THROUGH THE KOMEN BREAST CARE HELPLINE, THE PCC PROVIDED NEARLY 53,000 SERVICES TO OVER 38,000 PEOPLE THIS YEAR, INCLUDING: PROVIDING INFORMATION AND EDUCATIONAL RESOURCES ABOUT BREAST CANCER SCREENING AND TREATMENT OPTIONS. HELP WITH UNDERSTANDING A BREAST CANCER DIAGNOSIS. CONNECTIONS TO RESOURCES AND FINANCIAL SUPPORT. EMOTIONAL SUPPORT. ANOTHER IMPORTANT TOOL FOR KOMEN'S NAVIGATORS IS THE KOMEN FINANCIAL ASSISTANCE PROGRAM (KFA), WHICH ADDRESSES FINANCIAL BARRIERS TO CARE. WHILE MEDICAL TREATMENT AND MEDICAL CARE ARE THE PRIMARY COSTS ASSOCIATED WITH BREAST CANCER, THERE ARE OTHER COSTS OF DAILY LIVING THAT MAY PREVENT BREAST CANCER PATIENTS FROM COMPLETING TREATMENT. THE KFA HELPS INDIVIDUALS IN BREAST CANCER TREATMENT OR THOSE LIVING WITH METASTATIC BREAST CANCER (MBC), WHO HAVE AN ANNUAL INCOME AT OR BELOW 300% OF THE FEDERAL POVERTY LEVEL, PAY FOR COSTS ASSOCIATED WITH BASIC NEEDS LIKE HOUSING, TRANSPORTATION, GROCERIES, MEDICATIONS, CHILDCARE AND MORE. OVER 19,000 PEOPLE WERE SUPPORTED WITH NEARLY $11 MILLION IN FINANCIAL SUPPORT THROUGH KFA THIS YEAR. BY COVERING NECESSARY OUT-OF-POCKET COSTS, THE KFA INCREASES THE CHANCES THAT PEOPLE WILL CONTINUE WITH THEIR CARE, THEREBY DRIVING BETTER OUTCOMES. THE KOMEN PCC TEAM IS MADE UP OF MORE THAN 50 HIGHLY SKILLED PROFESSIONALS WHO ARE AS DIVERSE AS THOSE WE SERVE. OUR CARING AND COMPASSIONATE TEAM INCLUDES NAVIGATORS WITH SOCIAL WORK EXPERIENCE, BILINGUAL SPECIALISTS, SUBJECT MATTER EXPERTS, AND BREAST CANCER SURVIVORS FROM AROUND THE COUNTRY WHO UNDERSTAND THAT EVERYONE'S HEALTH CARE JOURNEY IS UNIQUE, THUS PROVIDING INDIVIDUALIZED CARE TO ENSURE THE BEST POSSIBLE OUTCOMES FOR EACH PERSON. KOMEN'S PCC MAKES CERTAIN THAT NO ONE FACES BREAST CANCER ALONE. WE ARE COMMITTED TO ADDRESSING BREAST HEALTH DISPARITIES THROUGH OUR TEAM OF EXPERTS BY MEETING PATIENTS WHERE THEY ARE AND HELPING THEM ACCESS HIGH-QUALITY BREAST CARE NO MATTER WHERE THEY LIVE AND FOR AS LONG AS THEY NEED IT. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS THE NONPARTISANVOICE for over 4 MILLION BREAST CANCER SURVIVORS, individuals LIVING WITH THE DISEASE and their supporters across the United. KOMEN WORKS TO EDUCATE PEOPLE ABOUT PUBLIC POLICY ISSUES SO THEY ARE EMPOWERED TO BECOME FORCEFUL ADVOCATES FOR THEMSELVES AND THEIR NEIGHBORS AND THEN UNITES THEIR COLLECTIVE VOICES FOR MAXIMUM IMPACT. THE CENTER FOR PUBLIC POLICY IS THE CORNERSTONE OF KOMEN'S MISSION, TO END BREAST CANCER FOREVER, THROUGH SOUND PUBLIC POLICY AND ADVOCACY COUPLED WITH SCIENTIFIC PROGRESS AND PATIENT SUPPORT SERVICES DESIGNED TO OVERCOME BARRIERS TO CARE. THE CENTER FOR PUBLIC POLICY IS THE DRIVING FORCE THAT ENSURES THE VOICE OF BREAST CANCER PATIENTS, SURVIVORS, CAREGIVERS, AND OTHER MEMBERS OF THE BREAST CANCER COMMUNITY ARE HEARD BY POLICYMAKERS ON LOCAL, STATE AND NATIONAL LEVELS. KOMEN BELIEVES THAT ONLY THROUGH INFORMED GOVERNMENT ACTION CAN BROAD, SYSTEMIC AND LASTING CHANGES BE MADE TO ENSURE THE NEEDS OF THE BREAST CANCER COMMUNITY ARE MET. KOMEN'S 2023-2024 POLICY AND ADVOCACY PRIORITIES INCLUDED: ACCELERATING RESEARCH BY SUPPORTING INCREASED STATE AND FEDERAL FUNDING FOR BREAST CANCER RESEARCH AND INCREASED CLINICAL TRIAL DIVERSITY; EXPANDING ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL PATIENT POPULATIONS; SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO REMOVE ADMINISTRATIVE BURDEN AND FINANCIAL BARRIERS TO SCREENING, DIAGNOSIS, AND TREATMENT INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PREVENT STEP THERAPY PROTOCOLS; AND ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC AND SUPPLEMENTAL BREAST IMAGING. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR POLICY AND ADVOCACY PRIORITIES, KOMEN ALSO ENGAGED ON ISSUES RELATED TO CUSTOM BREAST PROTHESES, GENETIC AND GENOMIC TESTING, LYMPHEDEMA, MEDICARE WAITING PERIODS, PALLIATIVE CARE, SURPRISE MEDICAL BILLING AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK.
Form 990, Part VI, Line 1a Executive Committee	THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES.
Form 990, Part VI, Line 15 OFFICES & POSITIONS FOR WHICH PROCESS WAS USED, & YEAR PROCESS WAS BEGUN	THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2023, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION.
Form 990, Part VI, Line 11b Review of form 990 by governing body	MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING.
Form 990, Part VI, Line 12c Conflict of interest policy	KOMEN'S CONFLICT OF INTEREST POLICY REQUIRES EVERY BOARD MEMBER, OFFICER, DIRECTOR, COMMITTEE MEMBER, ADVISORY BOARD MEMBER, EMPLOYEE, AND VOLUNTEER TO AVOID CONFLICTS OF INTEREST. IT ALSO REQUIRES THESE PERSONS TO REPORT ANY ACTUAL AND/OR POTENTIAL CONFLICTS OF INTEREST AS SOON AS POSSIBLE. REPORTS ARE REVIEWED BY THE GENERAL COUNSEL'S OFFICE AND/OR INTERNAL AUDIT, AND APPROPRIATE ACTION IS TAKEN PURSUANT TO THE CONFLICT OF INTEREST POLICY. FURTHER, KOMEN REQUIRES ALL BOARD MEMBERS, OFFICERS, DIRECTORS, COMMITTEE MEMBERS, ADVISORY BOARD MEMBERS, AND EMPLOYEES TO REVIEW AND EXECUTE THE CONFLICT OF INTEREST POLICY ANNUALLY AND DISCLOSE ANY ADDITIONAL ACTUAL/POTENTIAL CONFLICTS OF INTEREST. THESE ANNUAL DISCLOSURES ARE REVIEWED IN THE SAME MANNER. THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS RECEIVES, AND REVIEWS ALL REPORTED ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND THE RELATED ACTION TO ADDRESS THEM.
Form 990, Part VI, Line 19 Required documents available to the public	KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST.
Form 990, Part IX, Line 1	FOR NEARLY 40 YEARS, SUSAN G. KOMEN HAS WORKED TO FULFILL ITS VISION OF CREATING A WORLD WITHOUT BREAST CANCER THROUGH ITS MISSION OF SAVING LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO BETTER DETECT, PREVENT, TREAT BREAST CANCERS. OVER THE LAST THREE YEARS, KOMEN CONTINUED TO IMPLEMENT A SERIES OF CHANGES BEGUN IN 2020 TO STRENGTHEN ITS FINANCIAL AND OPERATIONAL POSITION IN RESPONSE TO THE CHANGING NEEDS OF THE BREAST CANCER COMMUNITY AND ECONOMIC CONDITIONS RESULTING FROM THE COVID-19 PANDEMIC. KOMEN HAS NEARLY COMPLETED THE CONSOLIDATION OF ALL OPERATIONS OF ITS INDEPENDENT AFFILIATES INTO ITS HEADQUARTERS ORGANIZATION, RESULTING IN A SINGLE ORGANIZATION. THIS CONSOLIDATION IS ENABLING KOMEN TO LEVERAGE THE COMBINED EXPERTISE OF ITS MISSION LEADERS TO DELIVER A UNITED MISSION PROGRAM, UTILIZING TECHNOLOGY AS A KEY DRIVER TO CONNECT TO PEOPLE WHO NEED TO ACCESS CARE WHERE THEY ARE AND TO HELP IMPROVE THE PATIENT EXPERIENCE, AS WELL AS RESULTED IN ADMINISTRATIVE AND OPERATIONAL EFFICIENCIES. CENTRAL TO KOMEN'S VISION IS A STEADFAST COMMITMENT TO INVESTING IN BREAKTHROUGH RESEARCH. KOMEN REMAINED COMMITTED TO INVESTING IN RESEARCH CENTERED ON THE PRIMARY FOCUS OF METASTATIC BREAST CANCER AND UNDERSTANDING AND ELIMINATING DISAPARITIES IN BREAST CANCER OUTCOMES BETWEEN BLACK AND WHITE PATIENTS. DESPITE THE ECONOMIC UNCERTAINTY AND CHALLENGING FUNDRAISING ENVIRONMENT, KOMEN AWARDED $40 MILLION IN NEW RESEARCH AWARDS OVER THE PAST TWO FISCAL YEARS. WHILE WE CONTINUE TO INVEST IN RESEARCH INTO NEW TREATMENTS, KOMEN SUPPORTS PEOPLE WHO ARE FACING BREAST CANCER TODAY THROUGH A GROWING SUITE OF PATIENT CARE SERVICES, INCLUDING DIRECT FINANCIAL ASSISTANCE THROUGH ITS TREATMENT ASSISTANCE PROGRAM, ELIGIBLE TO HELP PAY FOR EXPENSES THAT MAY SERVE AS A BARRIER TO ATTAINING THE CARE NEEDED TO SURVIVE, SUCH AS CO-PAYS, TRANSPORTATION, CHILDCARE OR RENT.
Form 990, Part XI, Line 9 Other changes in net assets or fund balances	RESCINDED GRANTS - 635650;